<DOC>
	<DOCNO>NCT01412164</DOCNO>
	<brief_summary>The study aim assess safety , efficacy performance delivery system FIREHAWK rapamycin-eluting stent five year .</brief_summary>
	<brief_title>Observational Registry Study : FIREHAWK DES Treating Coronary Artery Disease ( CAD )</brief_title>
	<detailed_description>This prospective open-labeled , multi-center , single-arm observational registry study . Approximately 1,100 subject enrol evaluate TLF primary endpoint 12-month . Also , study follow subject 5 year secondary endpoint .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age 1875 , male unpregnant woman Evidence nonsymptomatic ischemia , stable nonstable angina past MI Native coronary artery target lesion Target lesion length &lt; =60mm , target lesion vessel diameter 2.25mm4.0mm Target lesion diamter stenosis &gt; =70 % For target lesion , Firehawk stent implantation Understand study purpose , willing participate sign letter consent Acceptance clinical followup Actue MI within 72 hour Unprotected LM interventionrequired threevessel lesion Calcified lesion fail predilation twist lesion Bridge vessel lesion Any stent implant within one year Severe heart failure ( HYHA &gt; =III ) LVEF &lt; 40 % Renal deficiency , blood creatinine &gt; 2.0mg/dl Bleeding tendency Allergic aspirin , clopidogrel , ticlopidine , dye , ramapycin metal Life expectation &lt; 12 month History achieve study finish No compliance protocol Heart implantation subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>DES</keyword>
	<keyword>CAD</keyword>
	<keyword>FIREHAWK</keyword>
	<keyword>MicroPort</keyword>
	<keyword>PCI</keyword>
</DOC>